Our Mission

CMC-Rx Consultancy was created with the mission to provide unparallelled technical and operational management and oversight of CMC activities for Virtual Biotech companies.

We work remotely with drug developers in the US, Canada and Europe.

Who We Are

The company is currently headed by Jo Van Betsbrugge, PhD, President & Principal Consultant. Jo received training in Macromolecular and Physical Organic Chemistry (M. Sc), and in Synthetic Organic Chemistry (PhD), and counts over 20 years of industrial experience in Drug Development. He previously held the position of President at BioQuadrant Inc, where he helped create the first intranasal dry powder formulation to treat hypoglycemia (BAQSIMI(TM), Eli-Lilly). He is trained in the writing of CMC sections of INDs and NDAs. Experienced in the development and manufacture of a wide variety of chiral and achiral small molecules, as well as peptides and peptide mimetics, Jo has worked on the development of dual acting gluco-regulated insulin secretagogues, peripheral insulin sensitizers, HIV protease inhibitors, platelet inhibitors, thrombin inhibitors, bradykinin antagonists, thromboxane antagonists, high-potency opioid peptides, reactivators of acetylcholinesterase (AChE), Methylenetetrahydrofolate reductase (MTHFR)  inhibitors and  Phosphodiesterase inhibitors.

Jo is a member of the American Chemical Society (ACS) and the American Association of Pharmaceutical Scientists (AAPS).

CMC-Rx Consultancy was founded in 2018 by Myriam Triest, PhD. She holds the position of Vice-President & Senior Consultant Regulatory CMC. Myriam is trained at the PhD level in Physical Chemistry, and brings with her over 20 years of Drug Development experience. Myriam previously held the positions of Director of Product Development at Locemia Solutions,  VP Quality Assurance at BioQuadrant Pharmaceutical Intermediates Inc, and - most recently - Senior Director Technical Operations at a Appili Therapeutics.

Why Choose Us?